Some researchers found that mTORC2 passes NF-κB-mediated cisplatin resistance in GBM [32]; the EGFRvIII/PI3K/AKT/NF-κB pathway participates in TMZ resistance by regulating the key gene E2F6 of GBM drug resistance [16]. The gene discussed is E2F6; the disease is glioblastoma.